Margaret “Peggy” Dotzel
Former HHS and FDA Official Peggy Dotzel Rejoins Zuckerman Spaeder,
The PLN Round-up,
Former HHS and FDA Official Peggy Dotzel Rejoins Zuckerman Spaeder as Partner ,
HHS' Acting GC Under Obama Returns To Zuckerman Spaeder,
Zuckerman Spaeder Clients Win Lawsuits to Stop Cuts and End Implementation Delay of Changes to the 340B Drug Pricing Program,
Zuckerman Spaeder Clients Win Lawsuits to Stop Cuts and End Delay of Changes to the 340B Drug Pricing Program,
Zuckerman Spaeder’s Health Care Work is Again Recognized with a Law360 Practice Group of the Year Award,
Don't enact a law that diminishes the incentive for generic companies to challenge patents,
Interview of Stacy Cline Amin, Chief Counsel, FDA,
SCOTUS decision a boon to biopharmas in failure-to-warn cases,
Health Care Group Of The Year: Zuckerman Spaeder,
National Law Journal Names Zuckerman Spaeder a “D.C. Litigation Department of the Year”,
To Improve Competition In Generic Drug Markets, The FDA Should Discount User Fees For Small Players,
Legal Town Hall: Opportunities for Policies Favoring Generic Drugs Under the Biden Administration,
340B Coalition Summer Conference, Are We There Yet? Resolving the Contract Pharmacy Standoff,
A New Report Takes an Evidence-Based Approach to Analyzing the BLOCKING Act,
An Evidence-Based Assessment of the BLOCKING Act,
38 Zuckerman Spaeder Attorneys Recognized in 2023 Edition of The Best Lawyers in America, Including Three “Lawyers of the Year”,
Zuckerman Spaeder Win Restores Federal Drug Discount Program Savings,
Medicare's 340B Cuts For 2022 Must End Now, Judge Rules,
Zuckerman Spaeder's Beltway Office Shows its Pull as Place to Which Attorney Return,
GRx+Biosims 2022: Riders Considered in the User Fee Reauthorization,
Midterm Machinations: Law Firms Prepare for the November Congressional Reshuffle,
Former FDA Commissioners Call for Reversal of Mifepristone Decision, Warn of “Catastrophic” Consequences for Access to Medications,
42 Zuckerman Spaeder Attorneys, Including Six “Ones to Watch,” Recognized in 2024 Edition of The Best Lawyers in America,
Leading Healthcare Experts Oppose Lawsuit Challenging Medicare’s Drug Price Negotiation Program,
Nationally Recognized Healthcare Experts Oppose AstraZeneca’s Drug Price Negotiation Program Lawsuit,
Courts Have “Uniformly Rejected” Arguments Made in Drug Price Negotiation Program Lawsuit, According to Experts,
Over Two Dozen Zuckerman Spaeder Attorneys Named to the 2023 Capital Pro Bono Honor Roll,
Chambers USA Ranks Half of Zuckerman Spaeder Partners in 2024 Edition,
Best Lawyers® Recognizes 40 Zuckerman Spaeder Attorneys, Including Three “Lawyers of the Year” and Seven “Ones to Watch”,
Zuckerman Spaeder Continues to Grow Its Recognitions in the Latest Chambers USA Guide,
Nearly Half of Zuckerman Spaeder Attorneys Receive The Best Lawyers in America® Recognitions, Including Several “Ones to Watch”
